Advanced Biomed Inc operates through its subsidiary as an AI financial verification company focused on financial verification and other professional, regulated use cases. The Group develops and operates the FinTruth Financial Verification Agent Platform (FinTruth), an enterprise AI financial verification platform designed to compare and verify financial analysis and AI-generated financial content against underlying source documents and financial rules, and to produce source-traceable and auditable results. It focuses on establishing recurring and usage-based enterprise revenue from its AI technology operations. The Group has one reportable segment, consisting mainly of its technology and software-related operations.
Last trade$2.15
Day change-$0.07 (-3.15%)
Day range$2.10 – $2.30
Volume20,600
Market cap$4M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.67M
Price / earnings
0.6×
Price / book
0.32×
Price / sales
28.74×
EV / sales
27.06×
EV / EBITDA
-0.5×
Profitability
Earnings per share
$3.68
Return on assets
47.08%
Return on equity
53.82%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
8.09×
Quick ratio
8.09×
Cash ratio
0.13×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$1.51M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ADVB, quarterly periods
Line item
Q1 FY2027 Sep 30, 2026
Q4 FY2026 Jun 30, 2026
Q3 FY2026 Mar 31, 2026
Q2 FY2026 Dec 31, 2025
Q1 FY2026 Sep 30, 2025
Q4 FY2025 Jun 30, 2025
Q3 FY2025 Mar 31, 2025
Revenue
$0
$127.64K
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$127.64K
$0
$0
$0
$0
$0
Selling, general and administrative
$973.93K
$5.71M
$276.61K
$210.31K
$147.16K
$611.38K
$347.54K
Research and development
$0
-$665.14K
$243.23K
$186.33K
$0
-$600.06K
$219.97K
Total operating expenses
$973.93K
$5.05M
$519.84K
$396.64K
$147.16K
$11.32K
$567.51K
Operating income
-$973.93K
-$4.92M
-$519.84K
-$396.64K
-$147.16K
-$11.32K
-$567.51K
Interest expense
-$15.12K
-$7.01K
$0
$0
$0
$0
$0
Income before taxes
-$989.05K
-$12.52M
-$488.94K
$7M
-$147.16K
$675.64K
-$1.2M
Income taxes
$0
-$1.21K
$0
$0
$0
$0
$0
Net income
-$989.05K
$695K
-$488.94K
$6.86M
-$386.9K
-$701.61K
-$1.38M
Net income attributable to common shareholders
-$989.05K
$695K
-$488.94K
$6.86M
-$386.9K
-$701.61K
-$1.38M
EBITDA
-$973.93K
-$4.97M
-$510.51K
-$409.5K
-$147.16K
-$79.29K
-$545K
Basic earnings per share
-$0.60
$0.44
-$0.38
$6.20
-$0.36
-$0.65
-$1.35
Diluted earnings per share
-$0.60
$0.44
-$0.38
$6.20
-$0.36
-$0.65
-$1.35
Recent news
Company coverage with links to the original publishers.
Advanced Biomed Inc., a biotechnology company focused on cancer diagnostics and treatment, has announced the closing of its $6.56 million initial public offering on the Nasdaq Capital Market under the ticker symbol 'ADVB'.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.